Interestingly, some studies have shown that AR is also highly expressed in up to 70–90% of all breast cancer types, including as much as 30% of triple-negative breast cancers (TNBC) that are deficient in the expression of estrogen receptor α (ERα), progesterone receptor (PR) and HER2. Here, AR is linked to triple-negative breast carcinoma.